Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics reported Q1 2026 net revenue of $127.4 million, a significant increase from $39.1 million in Q1 2025, driven by strong DefenCath sales and the contribution from the Melinta portfolio. The company recorded net income of $38.6 million, or $0.48 per basic share, and adjusted EBITDA of $70.0 million, both showing substantial year-over-year growth. CorMedix raised its FY2026 guidance, now expecting net revenue in the range of $325 to $345 million and adjusted EBITDA in the range of $115 to $135 million.
Key figures
- Eps
- 0.48
- Eps Beat
- 0
- Revenue
- 127427000
- Guidance
- FY26 net revenue $325M-$345M, raised from prior; FY26 adjusted EBITDA $115M-$135M, raised from prior
- Revenue Yoy
- 226%
- Adjusted ebitda
- 69984000
- Defencath sales
- 97500000
- Melinta portfolio sales
- 29900000
- Cash and cash equivalents
- 178087000
- Non recurring sales allowance
- 9000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.